The Latest

BigHat Biosciences Announces First Patient Dosed in Phase 1 Trial Evaluating BHB810, a Novel CDH17-Directed Antibody-Drug Conjugate, for the Treatment of Gastric Cancer and other Advanced Gastrointestinal Tumors

BigHat Biosciences Appoints Stefan Weigand as Chief Scientific Officer

Behind the scenes: the platform connecting designs to data at scale

How to Get the Most out of Your Protein Language Model for Antibody Drug Design

Behind the scenes: the automation underneath BigHat’s in-house CFPS manufacturing

BigHat Biosciences Partners with Lilly to Advance Machine Learning–Enabled Biologics Discovery Through Lilly TuneLab

BigHat Announces Successful Completion of Our Strategic Collaboration with Johnson & Johnson

Introducing Reccy Antibody Design Studio (RADS)

BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics

BigHat’s Next Chapter: A Message from CEO Peyton Greenside

Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

BigHat featured on Genetic Engineering & Biotechnology News